Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1997 1
2000 1
2001 1
2002 1
2003 2
2008 1
2012 2
2013 2
2014 1
2015 1
2016 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

14 results
Results by year
Filters applied: . Clear all
Page 1
The protective effect of trimetazidine on myocardial ischemia/reperfusion injury through activating AMPK and ERK signaling pathway.
Liu Z, Chen JM, Huang H, Kuznicki M, Zheng S, Sun W, Quan N, Wang L, Yang H, Guo HM, Li J, Zhuang J, Zhu P. Liu Z, et al. Metabolism. 2016 Mar;65(3):122-30. doi: 10.1016/j.metabol.2015.10.022. Epub 2015 Oct 19. Metabolism. 2016. PMID: 26892523 Free PMC article.
TMZ changes the cardiac AMP/ATP ratio by modulating fatty acid oxidation, thereby triggering AMPK signaling cascade that contributes to the protection of the heart from ischemia/reperfusion (I/R) injury. ...RESULTS: TMZ treatment significantly stimulates cardiac AMP …
TMZ changes the cardiac AMP/ATP ratio by modulating fatty acid oxidation, thereby triggering AMPK signaling cascade that contributes …
Trimetazidine protects against smoking-induced left ventricular remodeling via attenuating oxidative stress, apoptosis, and inflammation.
Zhou X, Li C, Xu W, Chen J. Zhou X, et al. PLoS One. 2012;7(7):e40424. doi: 10.1371/journal.pone.0040424. Epub 2012 Jul 6. PLoS One. 2012. PMID: 22792312 Free PMC article.
In this study, Wistar rats were randomly divided into 3 groups: smoking group (exposed to cigarette smoke), trimetazidine group (exposed to cigarette smoke and treated with trimetazidine), and control group. ...Cardiomyocyte apoptotic rate was determined by f …
In this study, Wistar rats were randomly divided into 3 groups: smoking group (exposed to cigarette smoke), trimetazidine group (expo …
The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
MacInnes A, Fairman DA, Binding P, Rhodes Ja, Wyatt MJ, Phelan A, Haddock PS, Karran EH. MacInnes A, et al. Circ Res. 2003 Aug 8;93(3):e26-32. doi: 10.1161/01.RES.0000086943.72932.71. Epub 2003 Jul 17. Circ Res. 2003. PMID: 12869391
Trimetazidine acts as an effective antianginal clinical agent by modulating cardiac energy metabolism. Recent published data support the hypothesis that trimetazidine selectively inhibits long-chain 3-ketoacyl CoA thiolase (LC 3-KAT), thereby reducing
Trimetazidine acts as an effective antianginal clinical agent by modulating cardiac energy metabolism. Recent published
The metabolic modulator trimetazidine triggers autophagy and counteracts stress-induced atrophy in skeletal muscle myotubes.
Ferraro E, Giammarioli AM, Caldarola S, Lista P, Feraco A, Tinari A, Salvatore AM, Malorni W, Berghella L, Rosano G. Ferraro E, et al. FEBS J. 2013 Oct;280(20):5094-108. doi: 10.1111/febs.12484. Epub 2013 Sep 12. FEBS J. 2013. PMID: 23953053 Free article.
It has recently been demonstrated that trimetazidine (TMZ), an anti-ischemic antianginal agent, is also able to improve exercise performance in patients with peripheral arterial disease. TMZ is a metabolic modulator, and the mechanisms underlying its cytoprotective …
It has recently been demonstrated that trimetazidine (TMZ), an anti-ischemic antianginal agent, is also able to improve exerci …
Influence of trimetazidine on the synthesis of complex lipids in the heart and other target organs.
Sentex E, Héliès-Toussaint C, Rousseau D, Lucien A, Ferrary E, Grynberg A. Sentex E, et al. Fundam Clin Pharmacol. 2001 Aug;15(4):255-64. doi: 10.1046/j.1472-8206.2001.00031.x. Fundam Clin Pharmacol. 2001. PMID: 11564132
Trimetazidine exerts antianginal properties at the cellular level, without haemodynamic effect in clinical and experimental conditions. ...This study evaluated the influence of Trimetazidine on complex lipid synthesis from [2-(3)H] glycerol, in ventricular
Trimetazidine exerts antianginal properties at the cellular level, without haemodynamic effect in clinical and experimental co
Treatment with the 3-ketoacyl-CoA thiolase inhibitor trimetazidine does not exacerbate whole-body insulin resistance in obese mice.
Ussher JR, Keung W, Fillmore N, Koves TR, Mori J, Zhang L, Lopaschuk DG, Ilkayeva OR, Wagg CS, Jaswal JS, Muoio DM, Lopaschuk GD. Ussher JR, et al. J Pharmacol Exp Ther. 2014 Jun;349(3):487-96. doi: 10.1124/jpet.114.214197. Epub 2014 Apr 3. J Pharmacol Exp Ther. 2014. PMID: 24700885 Free PMC article.
Our aim was to determine whether treatment with the antianginal agent trimetazidine, which inhibits fatty acid oxidation in the heart secondary to inhibition of 3-ketoacyl-CoA thiolase (3-KAT), may have off-target effects on glycemic control in obesity. ...It is not …
Our aim was to determine whether treatment with the antianginal agent trimetazidine, which inhibits fatty acid oxidation in th …
The role of trimetazidine after acute myocardial infarction.
Banach M, Rysz J, Goch A, Mikhailidis DP, Rosano GM. Banach M, et al. Curr Vasc Pharmacol. 2008 Oct;6(4):282-91. doi: 10.2174/157016108785909788. Curr Vasc Pharmacol. 2008. PMID: 18855716 Review.
"Metabolic treatment" involves the use of drugs to improve cardiomyocyte function. Trimetazidine is the most investigated drugs in this group. ...The available data suggest that combined therapy of trimetazidine and haemodynamic drugs is an effective antia
"Metabolic treatment" involves the use of drugs to improve cardiomyocyte function. Trimetazidine is the most investigated drug …
The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
Rupp H, Zarain-Herzberg A, Maisch B. Rupp H, et al. Herz. 2002 Nov;27(7):621-36. doi: 10.1007/s00059-002-2428-x. Herz. 2002. PMID: 12439634 Review.
A shift from fatty acid oxidation to glucose oxidation leads to a reduced gluconeogenesis and improved economy of cardiac work. ...CLINICAL TRIALS with trimetazidine and ranolazine showed that this shift in substrate oxidation has an antianginal action. Etomo …
A shift from fatty acid oxidation to glucose oxidation leads to a reduced gluconeogenesis and improved economy of cardiac work. ...CL …
Trimetazidine demonstrated cardioprotective effects through mitochondrial pathway in a model of acute coronary ischemia.
Dehina L, Vaillant F, Tabib A, Bui-Xuan B, Chevalier P, Dizerens N, Bui-Xuan C, Descotes J, Blanc-Guillemaud V, Lerond L, Timour Q. Dehina L, et al. Naunyn Schmiedebergs Arch Pharmacol. 2013 Mar;386(3):205-15. doi: 10.1007/s00210-012-0826-z. Epub 2012 Dec 22. Naunyn Schmiedebergs Arch Pharmacol. 2013. PMID: 23263451
Trimetazidine (TMZ), a metabolic agent, is clinically used as an anti-anginal therapy. This study was conducted to compare the effect of TMZ 20 mg immediate release (IR) and TMZ 35 mg modified release (MR), two bioequivalent marketed formulations of TMZ, on cardioprotectio
Trimetazidine (TMZ), a metabolic agent, is clinically used as an anti-anginal therapy. This study was conducted to compare the effect
Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation.
Fantini E, Demaison L, Sentex E, Grynberg A, Athias P. Fantini E, et al. J Mol Cell Cardiol. 1994 Aug;26(8):949-58. doi: 10.1006/jmcc.1994.1116. J Mol Cell Cardiol. 1994. PMID: 7799450
This study was undertaken to evaluate the direct cardioprotective effect of trimetazidine (TMZ), an anti-anginal drug devoid of haemodynamic action, on isolated myocytes. ...H2O2 and 13-s-HpOTrE (13(S)-hydroperoxyoctadecatrienoic acid) during post-hypo …
This study was undertaken to evaluate the direct cardioprotective effect of trimetazidine (TMZ), an anti-anginal drug devoid of haemo …
14 results
Jump to page
Feedback